Michael S. Brown's most recent trade in Regeneron Pharmaceuticals, Inc. was a trade of 1,958 Non-Qualified Stock Option (right to buy) done . Disclosure was reported to the exchange on Jan. 2, 2025.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Regeneron Pharma | Michael S. Brown | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Jan 2025 | 1,958 | 1,958 | - | - | Non-Qualified Stock Option (right to buy) | |
| Regeneron Pharma | Michael S. Brown | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Jan 2025 | 166 | 1,548 (0%) | 0% | 0 | Common Stock | |
| Regeneron Pharma | Michael S. Brown | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 14 Jun 2024 | 1,535 | 0 | - | - | Non-Qualified Stock Option (right to buy) | |
| Regeneron Pharma | Michael S. Brown | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 625.60 per share. | 14 Jun 2024 | 1,535 | 2,917 (0%) | 0% | 625.6 | 960,296 | Common Stock |
| Regeneron Pharma | Michael S. Brown | Director | Sale of securities on an exchange or to another person at price $ 1040.00 per share. | 14 Jun 2024 | 1,535 | 1,382 (0%) | 0% | 1040 | 1,596,400 | Common Stock |
| Regeneron Pharma | Michael S. Brown | Director | Sale of securities on an exchange or to another person at price $ 974.86 per share. | 28 May 2024 | 1,172 | 1,382 (0%) | 0% | 974.9 | 1,142,536 | Common Stock |
| Regeneron Pharma | Michael S. Brown | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 625.60 per share. | 28 May 2024 | 1,172 | 2,554 (0%) | 0% | 625.6 | 733,203 | Common Stock |
| Regeneron Pharma | Michael S. Brown | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 28 May 2024 | 1,172 | 1,535 | - | - | Non-Qualified Stock Option (right to buy) | |
| Regeneron Pharma | Brown S. Michael | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Jan 2024 | 1,607 | 1,607 | - | - | Non-Qualified Stock Option (right to buy) | |
| Regeneron Pharma | Brown Michael S. | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Jan 2024 | 135 | 1,382 (0%) | 0% | 0 | Common Stock | |
| Regeneron Pharma | Brown S. Michael | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 482.68 per share. | 27 Dec 2023 | 2,049 | 3,296 (0%) | 0% | 482.7 | 989,011 | Common Stock |
| Regeneron Pharma | S. Brown Michael | Director | Sale of securities on an exchange or to another person at price $ 898.00 per share. | 27 Dec 2023 | 2,049 | 1,247 (0%) | 0% | 898 | 1,840,002 | Common Stock |
| Regeneron Pharma | Brown S. Michael | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 27 Dec 2023 | 2,049 | 0 | - | - | Non-Qualified Stock Option (right to buy) | |
| Regeneron Pharma | Michael S. Brown | Director | Sale of securities on an exchange or to another person at price $ 798.42 per share. | 21 Apr 2023 | 3,070 | 1,247 (0%) | 0% | 798.4 | 2,451,149 | Common Stock |
| Regeneron Pharma | Michael S. Brown | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 21 Apr 2023 | 3,070 | 0 | - | - | Non-Qualified Stock Option (right to buy) | |
| Regeneron Pharma | Michael S. Brown | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 520.01 per share. | 21 Apr 2023 | 3,070 | 4,317 (0%) | 0% | 520.0 | 1,596,431 | Common Stock |
| Regeneron Pharma | Michael S. Brown | Director | Sale of securities on an exchange or to another person at price $ 798.00 per share. | 06 Feb 2023 | 3,071 | 1,247 (0%) | 0% | 798 | 2,450,658 | Common Stock |
| Regeneron Pharma | Michael S. Brown | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 520.01 per share. | 06 Feb 2023 | 3,071 | 4,318 (0%) | 0% | 520.0 | 1,596,951 | Common Stock |
| Regeneron Pharma | Michael S. Brown | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 06 Feb 2023 | 3,071 | 3,070 | - | - | Non-Qualified Stock Option (right to buy) | |
| Regeneron Pharma | Michael S. Brown | Director | Sale of securities on an exchange or to another person at price $ 797.00 per share. | 06 Feb 2023 | 500 | 6,162 (0%) | 0% | 797 | 398,500 | Common Stock |
| Regeneron Pharma | Michael S. Brown | Director | Sale of securities on an exchange or to another person at price $ 747.00 per share. | 27 Jan 2023 | 1 | 1,247 (0%) | 0% | 747 | 747 | Common Stock |
| Regeneron Pharma | Michael S. Brown | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 27 Jan 2023 | 1 | 6,141 | - | - | Non-Qualified Stock Option (right to buy) | |
| Regeneron Pharma | Michael S. Brown | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 520.00 per share. | 27 Jan 2023 | 1 | 1,248 (0%) | 0% | 520 | 520 | Common Stock |
| Regeneron Pharma | Michael S. Brown | Director | Sale of securities on an exchange or to another person at price $ 747.14 per share. | 06 Jan 2023 | 3,070 | 1,247 (0%) | 0% | 747.1 | 2,293,720 | Common Stock |
| Regeneron Pharma | Michael S. Brown | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 06 Jan 2023 | 3,070 | 6,142 | - | - | Non-Qualified Stock Option (right to buy) | |
| Regeneron Pharma | Michael S. Brown | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 520.01 per share. | 06 Jan 2023 | 3,070 | 4,317 (0%) | 0% | 520.0 | 1,596,431 | Common Stock |
| Regeneron Pharma | Michael S. Brown | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Jan 2023 | 1,929 | 1,929 | - | - | Non-Qualified Stock Option (right to buy) | |
| Regeneron Pharma | Michael S. Brown | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Jan 2023 | 165 | 1,247 (0%) | 0% | 0 | Common Stock | |
| Regeneron Pharma | Michael S. Brown | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 374.12 per share. | 08 Nov 2022 | 2,431 | 3,513 (0%) | 0% | 374.1 | 909,486 | Common Stock |
| Regeneron Pharma | Michael S. Brown | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 08 Nov 2022 | 2,431 | 0 | - | - | Non-Qualified Stock Option (right to buy) | |
| Regeneron Pharma | Michael S. Brown | Director | Sale of securities on an exchange or to another person at price $ 748.48 per share. | 08 Nov 2022 | 1,764 | 1,749 (0%) | 0% | 748.5 | 1,320,319 | Common Stock |
| Regeneron Pharma | Michael S. Brown | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 08 Nov 2022 | 1,564 | 2,049 | - | - | Non-Qualified Stock Option (right to buy) | |
| Regeneron Pharma | Michael S. Brown | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 482.68 per share. | 08 Nov 2022 | 1,564 | 3,313 (0%) | 0% | 482.7 | 754,912 | Common Stock |
| Regeneron Pharma | Michael S. Brown | Director | Sale of securities on an exchange or to another person at price $ 748.49 per share. | 08 Nov 2022 | 500 | 6,662 (0%) | 0% | 748.5 | 374,245 | Common Stock |
| Regeneron Pharma | Michael S. Brown | Director | Sale of securities on an exchange or to another person at price $ 753.66 per share. | 08 Nov 2022 | 300 | 2,684 (0%) | 0% | 753.7 | 226,098 | Common Stock |
| Regeneron Pharma | Michael S. Brown | Director | Sale of securities on an exchange or to another person at price $ 752.14 per share. | 08 Nov 2022 | 203 | 2,984 (0%) | 0% | 752.1 | 152,684 | Common Stock |
| Regeneron Pharma | Michael S. Brown | Director | Sale of securities on an exchange or to another person at price $ 767.25 per share. | 08 Nov 2022 | 201 | 1,282 (0%) | 0% | 767.2 | 154,217 | Common Stock |
| Regeneron Pharma | Michael S. Brown | Director | Sale of securities on an exchange or to another person at price $ 766.74 per share. | 08 Nov 2022 | 201 | 1,483 (0%) | 0% | 766.7 | 154,115 | Common Stock |
| Regeneron Pharma | Michael S. Brown | Director | Sale of securities on an exchange or to another person at price $ 768.11 per share. | 08 Nov 2022 | 200 | 1,082 (0%) | 0% | 768.1 | 153,622 | Common Stock |
| Regeneron Pharma | Michael S. Brown | Director | Sale of securities on an exchange or to another person at price $ 764.23 per share. | 08 Nov 2022 | 200 | 1,784 (0%) | 0% | 764.2 | 152,846 | Common Stock |
| Regeneron Pharma | Michael S. Brown | Director | Sale of securities on an exchange or to another person at price $ 763.19 per share. | 08 Nov 2022 | 200 | 1,984 (0%) | 0% | 763.2 | 152,638 | Common Stock |
| Regeneron Pharma | Michael S. Brown | Director | Sale of securities on an exchange or to another person at price $ 760.70 per share. | 08 Nov 2022 | 200 | 2,284 (0%) | 0% | 760.7 | 152,140 | Common Stock |
| Regeneron Pharma | Michael S. Brown | Director | Sale of securities on an exchange or to another person at price $ 754.70 per share. | 08 Nov 2022 | 200 | 2,484 (0%) | 0% | 754.7 | 150,940 | Common Stock |
| Regeneron Pharma | Michael S. Brown | Director | Sale of securities on an exchange or to another person at price $ 751.23 per share. | 08 Nov 2022 | 126 | 3,187 (0%) | 0% | 751.2 | 94,655 | Common Stock |
| Regeneron Pharma | Michael S. Brown | Director | Sale of securities on an exchange or to another person at price $ 765.19 per share. | 08 Nov 2022 | 100 | 1,684 (0%) | 0% | 765.2 | 76,519 | Common Stock |
| Regeneron Pharma | Michael S. Brown | Director | Sale of securities on an exchange or to another person at price $ 761.53 per share. | 08 Nov 2022 | 100 | 2,184 (0%) | 0% | 761.5 | 76,153 | Common Stock |
| Regeneron Pharma | Michael S. Brown | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 29 Mar 2022 | 1,522 | 2,839 | - | - | Non-Qualified Stock Option (right to buy) | |
| Regeneron Pharma | Michael S. Brown | Director | Sale of securities on an exchange or to another person at price $ 699.00 per share. | 29 Mar 2022 | 1,522 | 1,082 (0%) | 0% | 699 | 1,063,878 | Common Stock |
| Regeneron Pharma | Michael S. Brown | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 374.12 per share. | 29 Mar 2022 | 1,522 | 2,604 (0%) | 0% | 374.1 | 569,411 | Common Stock |
| Regeneron Pharma | Michael S. Brown | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 29 Mar 2022 | 408 | 2,431 | - | - | Non-Qualified Stock Option (right to buy) | |
| Regeneron Pharma | Michael S. Brown | Director | Sale of securities on an exchange or to another person at price $ 699.00 per share. | 29 Mar 2022 | 408 | 1,082 (0%) | 0% | 699 | 285,192 | Common Stock |
| Regeneron Pharma | Michael S. Brown | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 374.12 per share. | 29 Mar 2022 | 408 | 1,490 (0%) | 0% | 374.1 | 152,641 | Common Stock |
| Regeneron Pharma | Michael S. Brown | Director | Sale of securities on an exchange or to another person at price $ 608.68 per share. | 23 Feb 2022 | 500 | 7,162 (0%) | 0% | 608.7 | 304,340 | Common Stock |
| Regeneron Pharma | Michael S. Brown | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Jan 2022 | 2,707 | 2,707 | - | - | Non-Qualified Stock Option (right to buy) | |
| Regeneron Pharma | Michael S. Brown | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Jan 2022 | 191 | 1,082 (0%) | 0% | 0 | Common Stock | |
| Regeneron Pharma | Michael S. Brown | Director | Sale of securities on an exchange or to another person at price $ 651.10 per share. | 13 Sep 2021 | 3,712 | 953 (0%) | 0% | 651.1 | 2,416,883 | Common Stock |
| Regeneron Pharma | Michael S. Brown | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 13 Sep 2021 | 3,613 | 3,612 | - | - | Non-Qualified Stock Option (right to buy) | |
| Regeneron Pharma | Michael S. Brown | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 413.33 per share. | 13 Sep 2021 | 3,613 | 6,983 (0%) | 0% | 413.3 | 1,493,361 | Common Stock |
| Regeneron Pharma | Michael S. Brown | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 13 Sep 2021 | 3,612 | 0 | - | - | Non-Qualified Stock Option (right to buy) | |
| Regeneron Pharma | Michael S. Brown | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 413.33 per share. | 13 Sep 2021 | 3,612 | 10,595 (0%) | 0% | 413.3 | 1,492,948 | Common Stock |
| Regeneron Pharma | Michael S. Brown | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 13 Sep 2021 | 2,479 | 0 | - | - | Non-Qualified Stock Option (right to buy) | |
| Regeneron Pharma | Michael S. Brown | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 380.95 per share. | 13 Sep 2021 | 2,479 | 3,370 (0%) | 0% | 380.9 | 944,375 | Common Stock |
| Regeneron Pharma | Michael S. Brown | Director | Sale of securities on an exchange or to another person at price $ 650.40 per share. | 13 Sep 2021 | 1,800 | 4,665 (0%) | 0% | 650.4 | 1,170,720 | Common Stock |
| Regeneron Pharma | Michael S. Brown | Director | Sale of securities on an exchange or to another person at price $ 648.48 per share. | 13 Sep 2021 | 962 | 7,303 (0%) | 0% | 648.5 | 623,838 | Common Stock |
| Regeneron Pharma | Michael S. Brown | Director | Sale of securities on an exchange or to another person at price $ 649.46 per share. | 13 Sep 2021 | 838 | 6,465 (0%) | 0% | 649.5 | 544,247 | Common Stock |
| Regeneron Pharma | Michael S. Brown | Director | Sale of securities on an exchange or to another person at price $ 638.64 per share. | 13 Sep 2021 | 676 | 9,619 (0%) | 0% | 638.6 | 431,721 | Common Stock |
| Regeneron Pharma | Michael S. Brown | Director | Sale of securities on an exchange or to another person at price $ 642.62 per share. | 13 Sep 2021 | 400 | 8,816 (0%) | 0% | 642.6 | 257,048 | Common Stock |
| Regeneron Pharma | Michael S. Brown | Director | Sale of securities on an exchange or to another person at price $ 639.20 per share. | 13 Sep 2021 | 203 | 9,416 (0%) | 0% | 639.2 | 129,758 | Common Stock |
| Regeneron Pharma | Michael S. Brown | Director | Sale of securities on an exchange or to another person at price $ 637.29 per share. | 13 Sep 2021 | 200 | 10,295 (0%) | 0% | 637.3 | 127,458 | Common Stock |
| Regeneron Pharma | Michael S. Brown | Director | Sale of securities on an exchange or to another person at price $ 647.58 per share. | 13 Sep 2021 | 151 | 8,265 (0%) | 0% | 647.6 | 97,785 | Common Stock |
| Regeneron Pharma | Michael S. Brown | Director | Sale of securities on an exchange or to another person at price $ 646.28 per share. | 13 Sep 2021 | 100 | 8,416 (0%) | 0% | 646.3 | 64,628 | Common Stock |
| Regeneron Pharma | Michael S. Brown | Director | Sale of securities on an exchange or to another person at price $ 645.66 per share. | 13 Sep 2021 | 100 | 8,516 (0%) | 0% | 645.7 | 64,566 | Common Stock |
| Regeneron Pharma | Michael S. Brown | Director | Sale of securities on an exchange or to another person at price $ 644.89 per share. | 13 Sep 2021 | 100 | 8,616 (0%) | 0% | 644.9 | 64,489 | Common Stock |
| Regeneron Pharma | Michael S. Brown | Director | Sale of securities on an exchange or to another person at price $ 643.49 per share. | 13 Sep 2021 | 100 | 8,716 (0%) | 0% | 643.5 | 64,349 | Common Stock |
| Regeneron Pharma | Michael S. Brown | Director | Sale of securities on an exchange or to another person at price $ 641.12 per share. | 13 Sep 2021 | 100 | 9,216 (0%) | 0% | 641.1 | 64,112 | Common Stock |
| Regeneron Pharma | Michael S. Brown | Director | Sale of securities on an exchange or to another person at price $ 640.77 per share. | 13 Sep 2021 | 100 | 9,316 (0%) | 0% | 640.8 | 64,077 | Common Stock |
| Regeneron Pharma | Michael S. Brown | Director | Sale of securities on an exchange or to another person at price $ 636.74 per share. | 13 Sep 2021 | 100 | 10,495 (0%) | 0% | 636.7 | 63,674 | Common Stock |
| Regeneron Pharma | Michael S. Brown | Director | Sale of securities on an exchange or to another person at price $ 652.26 per share. | 13 Sep 2021 | 62 | 891 (0%) | 0% | 652.3 | 40,440 | Common Stock |
| Regeneron Pharma | Michael S. Brown | Director | Sale of securities on an exchange or to another person at price $ 612.38 per share. | 09 Aug 2021 | 1,687 | 7,662 (0%) | 0% | 612.4 | 1,033,085 | Common Stock |
| Regeneron Pharma | Michael S. Brown | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 25 Jun 2021 | 2,084 | 0 | - | - | Non-Qualified Stock Option (right to buy) | |
| Regeneron Pharma | Michael S. Brown | Director | Sale of securities on an exchange or to another person at price $ 549.00 per share. | 25 Jun 2021 | 2,084 | 891 (0%) | 0% | 549 | 1,144,116 | Common Stock |
| Regeneron Pharma | Michael S. Brown | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 371.40 per share. | 25 Jun 2021 | 2,084 | 2,975 (0%) | 0% | 371.4 | 773,998 | Common Stock |
| Regeneron Pharma | Michael S. Brown | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 380.95 per share. | 25 Jan 2021 | 2,480 | 3,371 (0%) | 0% | 381.0 | 944,756 | Common Stock |
| Regeneron Pharma | Michael S. Brown | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 25 Jan 2021 | 2,480 | 2,479 | - | - | Non-Qualified Stock Option (right to buy) | |
| Regeneron Pharma | Michael S. Brown | Director | Sale of securities on an exchange or to another person at price $ 554.32 per share. | 25 Jan 2021 | 2,480 | 891 (0%) | 0% | 554.3 | 1,374,714 | Common Stock |
| Regeneron Pharma | Michael S. Brown | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 04 Jan 2021 | 3,613 | 3,613 | - | - | Non-Qualified Stock Option (right to buy) | |
| Regeneron Pharma | Michael S. Brown | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 04 Jan 2021 | 248 | 891 (0%) | 0% | 0 | Common Stock | |
| Regeneron Pharma | Michael S. Brown | Director | Sale of securities on an exchange or to another person at price $ 552.36 per share. | 22 Sep 2020 | 5,090 | 643 (0%) | 0% | 552.4 | 2,811,512 | Common Stock |
| Regeneron Pharma | Michael S. Brown | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 22 Sep 2020 | 2,610 | 0 | - | - | Non-Qualified Stock Option (right to buy) | |
| Regeneron Pharma | Michael S. Brown | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 376.69 per share. | 22 Sep 2020 | 2,610 | 5,733 (0%) | 0% | 376.7 | 983,161 | Common Stock |
| Regeneron Pharma | Michael S. Brown | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 22 Sep 2020 | 2,480 | 4,959 | - | - | Non-Qualified Stock Option (right to buy) | |
| Regeneron Pharma | Michael S. Brown | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 380.95 per share. | 22 Sep 2020 | 2,480 | 3,123 (0%) | 0% | 381.0 | 944,756 | Common Stock |
| Regeneron Pharma | Michael S. Brown | Director | Sale of securities on an exchange or to another person at price $ 552.36 per share. | 22 Sep 2020 | 1,000 | 9,349 (0%) | 0% | 552.4 | 552,360 | Common Stock |
| Regeneron Pharma | Michael S. Brown | Director | Gift of securities by or to the insider at price $ 0.00 per share. | 22 Sep 2020 | 1,000 | 10,349 (0%) | 0% | 0 | Common Stock |